Announcements

19 August 2024
MDPI’s 2023 Young Investigator Awards—Winners Announced


MDPI’s Young Investigator Awards recognize promising early career scientists, acknowledge their contributions, and foster collaboration within the scientific community. We are proud to announce the recipients for 2023, who were carefully selected by the journals’ esteemed Award Evaluation Committee.

We extend our heartfelt congratulations to the 79 winners of MDPI’s 2023 Young Investigator Awards for their excellent contributions in their research field. We look forward to seeing these rising stars continue to contribute to the advancement of science.

MDPI will continue to support and recognize the academic community. To explore details about the awardees by field, please visit the individual pages listed below:

Congratulations to all the winners for their exceptional contributions and dedication to advancing scientific research.

About MDPI Awards:
To support the academic community, particularly young researchers, and to enhance communication among scientists, MDPI journals regularly offer various awards to researchers in specific fields. These awards, serving as a source of inspiration and recognition, help to elevate the profiles of talented individuals who have made outstanding achievements and are making significant contributions to advancements in their respective fields.

To find out more about MDPI awards, please click here.

16 August 2024
Recruiting Early Career Editorial Board Members for Antibodies


In order to further enhance the international influence of the journal Antibodies (ISSN:2073-4468), promote the academic exchange of young scientists, and support the Editorial Board with additional expertise, the first Early Career Editorial Board of Antibodies (2024–2025) is being set up, and outstanding young scholars are invited to join!

Recruitment:
We plan on recruiting a total of 30 Early Career Editorial Board Members. Early Career Editorial Board (ECEB) members will hold the position for two years with the possibility of renewal for a second term.

The eligibility criteria for applicants are as follows:

  • Completed their doctorate/Ph.D. degree in the past 10 years (considering exceptions for career interruptions, including medical and family leave);
  • Significant research achievements in the field of antibodies and antigens, antibodies and the humoral immune response, discovery, generation and selection of antibodies, antibody structure and function, antibody engineering, conjugates and fusion proteins, antibodies in biomedical research and therapy;
  • Willingness to dedicate their time to the development of the journal with passion and enthusiasm;
  • Researchers that are active and engaged in their community (e.g., experienced at presenting at academic conferences or involved in professional organizations).

The benefits of being an Early Career Editorial Board Member include:

  • A certificate of appointment as an Early Career Editorial Board Member will be provided;
  • The achievements of Early Career Editorial Board Members are publicized on journal media platforms to improve academic visibility;
  • An opportunity to be promoted to Editorial Board Member based on contributions;
  • The journal will regularly acknowledge those who participated in the peer-review process on the journal website;
  • Opportunities to participate in or host annual meetings and online seminars organized by the Editor-in-Chief and the Editorial Board Members.

Responsibilities of an Early Career Editorial Board Member include:

  • Publicizing and promoting the journal at academic conferences and among peers;
  • Selecting high-quality articles and preparing bilingual media content for promotion;
  • Reviewing at least four manuscripts per year;
  • Providing input on any new initiatives of journal development;
  • Inviting submissions from local and overseas world-leading scientists in respective research fields.

To apply, please undertake the following steps:
Please fill in the application form here.

Please send the application form and your academic resume to antibodies@mdpi.com with the subject of “Antibodies Early Career Editorial Board Application + Name + Institute + Research Expertise”.

Application deadline: 1 January 2025.

Selection Process and Announcement:
The selection process will include an initial screening of application materials → selection by the Editor-in-Chief and Editorial Board Members → email notification → issuing a certificate of appointment.

7 August 2024
MDPI Insights: The CEO's Letter #14 - New Headquarters, Marketing, Poland

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Moves to New Headquarters in Basel, Switzerland

I am excited to share that MDPI has moved to a new state-of-the-art office space in Basel, Switzerland. This move consolidates our operations by bringing together our two previously separated Basel offices into one central location.

We are always growing our talent pool and encourage you to view our Careers Page for the positions available in Basel and across our offices.

New Address: Grosspeteranlage 5, CH-4052 Basel, Switzerland

Effective Date: 1 July 2024

This new chapter in our company’s journey is designed to continue our mission of positioning MDPI as a leader in Open Access (OA) publishing, highlighting our commitment to making scholarly research accessible to everyone.

Boasting modern amenities, improved meeting and event spaces designed to support our growing needs, the new location provides a more collaborative and efficient working environment for our employees. The location offers convenient accessibility to public transportation and is situated near the Basel SBB railway station, with a variety of nearby services and amenities.

In fact, I can see the trains right outside of my window as I write these lines!

This move marks an exciting milestone in MDPI’s development, and I am confident that the new headquarters will serve as an inspiring and productive space for everyone. We also very much look forward to welcoming visitors here. You can read more about MDPI's history here.

“This new chapter continues our mission of positioning MDPI as a leader in OA publishing”

For Those New to MDPI

A pioneer in scholarly, Open Access publishing, MDPI has supported academic communities since 1996. MDPI is leading the transition to Open Science by making a greater proportion of the research conducted worldwide free and accessible to everyone. To date, over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6,000 professional, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes within its 440 fully Open Access titles. MDPI supports more than 800 academic institutions worldwide, helping them adhere to national mandates while facilitating authors’ publication in fully compliant (CC BY) Open Access journals.

Impactful Research

New and Emerging MDPI Journals Making an Immediate Impact

Unpacking some of the Impact Factor updates from the June CEO Letter, I wanted to dive a little deeper into the 137 MDPI journals which received Impact Factor for the first time.

Academic authors highly value efficient publishing processes, robust editorial support, and the opportunity to publish in high-impact journals. We are proud that our newly launched journals typically achieve coverage in the Emerging Sources Citation Index (ESCI) of the Web of Science within just a few years, with a median time of only three years from release to inclusion.

As part of our commitment to advancing academic research and providing high-quality OA publishing, we actively seek new research areas to expand our portfolio of journals. We have a proven track record of successfully establishing new journals.

Our dedicated teams excel in fostering dynamic editorial boards and working closely with Editors-in-Chief (EiC) to define the precise scope and focus of each new journal. Our expertise extends to collaborating with indexing services, ensuring that our journals comply with best practices and are indexed promptly in all relevant databases.

Emerging Titles Ranked for the First Time

Our commitment to excellence is reflected in the annual impact metrics released this past June. The latest edition of the Journal Citation Reports (JCR) showcases the integration of journals from the ESCI in the new unified category rankings, providing a simplified and more complete view of all journals within each subject category, including newly established titles.

Out of 137 new and developing MDPI journals ranked in the 2024 release, 79 are in the top half (Q1 or Q2) of their categories. Here is a breakdown of the number of MDPI’s ESCI-indexed journals by quartile in the JCR:

Quartile No. of journals
Q1 17 (12.4%)
Q2 62 (45.3%)
Q3 43 (31.4%)
Q4 15 (10.9%)
Not ranked (humanities-related journals) 2

These rankings highlight our success in rapidly establishing high-impact new journals. Among those that made it directly into the top 25% of their category are the International Journal of Neonatal Screening, Journal of Xenobiotics, Polysaccharides, Smart Cities, and thirteen other journals.

You can browse MDPI journals by Indexing. Simply visit our Journals page and select from the list of Indexing bodies in the top left-hand corner.

For quick reference, as at 31 July 2024:

Inside MDPI

MDPI Corporate Marketing Strategy and Team Meeting 2024

In July, I hosted the annual Corporate Marketing strategy and team-building activity with 15 of our team members.

The aim was to align the Corporate Marketing strategy with MDPI's goal of becoming the world's most trusted OA publisher. While we provide a high-level publishing experience for our authors, as seen from our surveys, we need to keep building on our transparent and open communication to foster trust within the scholarly community and continue enhancing our reputation.

The Corporate Marketing team plays an important role as the mouthpiece for all our major activities within MDPI, especially those that model what it means to be a trusted partner. The purpose of the strategy meeting was to develop a feeling of trust in one another and an understanding of how to inspire trust in the stakeholders with whom we interact.

“We need to keep building on our transparent and open communication to foster trust within the scholarly community”

We conducted a set of activities to facilitate that sense of mutual trust and trustworthiness. Examples of some activities we worked on during this strategy-building event include:

  • Exploring what trust means
    • ‘Letter to self’
    • ‘The brand I most trust’
  • Most Trusted Academic Publisher
    • ‘The brand I would like MDPI to become’
    • ‘The 2029 MDPI Annual Report’
    • Voice of Customer and Share of Voice – survey/data update on MDPI Brand Experience and Brand Perception
  • Integrate Trust-Based Objective into Marketing Plan
    • ‘Becoming the MDPI experience’
    • ‘Trusting the next steps’

While two days is not enough to finalize a marketing strategy, it is sufficient to get everyone who attended into the mindset of the direction in which we are working. From here, we will develop a program with next steps on main projects, update communications, and collaborate with team leads to incorporate this approach into our work going forward.

As a marketing team, we can communicate our messages, but trust has to be built at every touchpoint in the stakeholder journey. Just talking about it isn’t enough. We need to be about it. That’s a role each of us plays, from editorial to IT, from marketing to HR. We must build trust from the inside out. It starts with each manager and resonates out via every team member.

As a company, our goal is to give all stakeholders with whom we interact – whether internal or external – the experience of working with an organization it can trust.

Coming Together for Science

MDPI in Poland: Krakow Office

In July, I had the pleasure of visiting our Krakow office, following my recent trip to Warsaw to meet with the Polish Ministry of Science and Higher Education.

During these visits, I prioritized meeting with our Office Manager, Editorial Director, Group Leads, and members from various teams, including editorial, production, marketing, and journal relationship specialists, to understand their roles and current challenges. Instead of a formal presentation, I opted for an open discussion, sharing updates from headquarters to engage with colleagues in a more personal way.

Our Krakow office has many things to be proud of, including a large number of PhD colleagues (over a third of its staff holds a PhD degree). Krakow provides an opportunity for expanding beyond the 100 colleagues we currently have, by adding new hires in departments including editorial, production and marketing, among others.

About our Krakow office

  • Opened in 2020
  • 99 staff members as at 1 August 2024
  • Main Departments include Editorial, Production, English Department, JRS, PR

Our Krakow office participates in international conferences, conducts author trainings and scholar visits, and engages in local market outreach. The office is also a member of the Polish Chamber of Commerce for High Technology (IZTECH) and is working on expanding its local engagement.

Krakow is the second-largest city in Poland, with a population of about 800,000. It also has a large student population of around 128,000, with seven universities. This means that roughly one in every eight residents is a student.

Poland and MDPI

Poland is a crucial market for MDPI. From 2020 to June 2024, Poland ranked 7th in submissions and 5th in publications for MDPI research articles. As at 31 July 2024, Poland ranks 7th in total MDPI publications, with approximately 70,000 research papers.

Between 2020 and June 2024, 61,500 authors from Poland published with MDPI. As at 30 June 2024, there are 1,205 active Editorial Board Members (EBMs) from Poland, with 661 EBMs (55% of the total) having an H-index over 25.

We also have four Editors-in-Chief (EiC) from Poland leading our journals: Coatings, Venereology, Advances in Respiratory Medicine, and Limnological Review, along with six Section EiC.

In 2023, we received approximately 21,000 submissions from Polish-affiliated authors, of which 12,032 were published.

“Poland is a crucial market for MDPI”

Meeting with Ministry of Education

On 22 July, we visited Warsaw to meet with the Polish Ministry of Science and Higher Education.

We were pleased to learn that they are strong supporters of the OA publishing model and value MDPI’s approach to the peer-review process, including our high ethical standards for quality control.

In 2023 Polish authors predominantly published their papers in OA, with MDPI holding the largest market share in OA publications within the country.

Our commitment to collaborating with Polish institutions is evident through our 33 Institutional Open Access Program (IOAP) agreements with prestigious institutions such as the University of Warsaw, the University of Wroclaw, the Jagiellonian University, and Gdańsk University of Technology. Through IOAP discounts, a healthy waiver rate, and our peer-review voucher system, we provide the Polish scholarly community with significant savings in OA publishing. The Minister greatly appreciated these efforts and our commitment to offsetting some of the APC costs.

We discussed industry concerns about the threat of papermills and presented the preventive measures MDPI has in place to mitigate this risk and uphold high ethical standards. We informed them of our commitment to combating papermills, including our involvement with United2Act and the STM Research Integrity Hub, as well as our efforts to expand our research integrity team and explore proactive measures.

Closing Thoughts

MDPI Thought Leadership Op-ed on Open Access is Now Live on Politico

I am pleased to share that our thought leadership Op-ed piece on Open Access (OA) is now live on Politico. This is a nice push for continued influence and support of OA among policymakers and industry leaders.

Why Politico?

Politico's reputation as a highly credible and influential news platform makes it an important venue to reach key opinion leaders (KOL) from academia, policymakers, and thought leaders from many industries. This visibility helps promote the OA philosophy.

Open Access: A Moral Imperative for Progress

In this piece, I discuss the necessity of making scientific research freely available to all. I argue that publicly funded research should be publicly accessible, highlighting how OA democratizes scientific knowledge, accelerates research availability, and fosters collaboration.

“Open Access is a fundamental right for all citizens”

Democratizing scientific communication
The impulse to democratize scientific communication is nothing new. OA may seem like a recent innovation, but its principles have historical roots traceable to Europe in the 15th century. Just as the printing revolution accelerated the dissemination of new ideas, OA publishing unlocks new scientific insights that would otherwise only be accessible to a few.

Benefits for scholars: amplifying impact through Open Access
Authors publishing in an OA journal can expect more citations of their work, increasing its potential impact. Research findings that are freely available are more likely to be cited than those hidden behind a paywall. Freedom of access greatly increases the potential audience for each paper, fostering a sense of community among researchers worldwide. Heightened visibility can attract prospective collaborators and employers for young scientists. At MDPI, we believe that all these factors can only accelerate the advance of science. Additionally, authors retain copyright in their work instead of signing it away, permitting broader dissemination under Creative Commons licenses and increasing its capacity for impact.

The moral imperative
OA is not just a matter of scientific policy; it is a fundamental right for all citizens and a prerequisite for a brighter, more informed future. Publicly funded research should be a top priority, and I am pleased to see policy moving in this direction. Our capacity to generate transformative scientific insights has to be democratized. The question today is no longer whether we can afford to embrace OA; rather, it is whether we can afford not to.

Stefan Tochev
Chief Executive Officer
MDPI AG

2 August 2024
MDPI Romania Author Training Sessions in May

In May, MDPI Romania held three author training sessions – one endorsing an external event and two stand-alone sessions.

The National Session of Scientific Student Communications took place at Technical University Cluj on 17 and 18 May 2024. MDPI Romania sponsored this event and contributed an author training session on the production of research papers and case study analyses. JRS Norbert Kiss gave a presentation called The World of Open Access to explain different open access publishing models and the benefits of open access publishing. His presentation highlighted the impact of open access publishing on scientific progress and innovation.

On 29 May 2024, MDPI Romania hosted an author training session for Ph.D. students, early career researchers, and professors at the Carol Davila University of Medicine and Pharmacy. In collaboration with Prof. Andreea Arsene, JRS Ioana Paunescu prepared two presentations: The Steps of the Publishing Process and Elaboration of a Peer Review Report. In her first presentation, she delved into MDPI’s history and mission, MDPI’s editorial process, and MDPI journals of various scopes that are accepting submissions. Her second presentation outlined the types of peer review, the contents of a peer review report by an MDPI reviewer, and the responsibilities of an MDPI reviewer.

MDPI Romania also hosted an author training session at the Iasi University of Life Sciences on 29 May 2024. JRSs Laurentiu Preda and Cosmin Artan gave four presentations: Efficient Writing of an ISI-Indexed Scientific Article, Benefits of Publishing in the Open Access Model, Various Methods of Open Access Publishing, and MDPI Guide for the Article Review Process. The first three presentations offered guidance on how to improve academic writing, the fourth focused on how to write peer review reports. A highly interactive discussion followed the presentations, during which the JRSs provided extensive answers to attendees’ questions.

MDPI is grateful for all the attendees, speakers, and organizers involved in these events. Through their enthusiasm and dedication, these events were great successes.

10 July 2024
MDPI's Newly Launched Journals in June 2024

Five new journals covering multiple subjects have launched their inaugural issue in June 2024. We are excited to be able to share with you the newest research rooted in the value of open access.

We would like to express our deepest appreciation to all the Editorial Board Members and each journal will ensure its high-quality output using excellent editorial and rigorous peer review processes, to ensure that the articles achieve high impact and visibility.

Please feel free to browse and discover more about the new journals below.

Journal

Founding Editor-in-Chief

Journal Topics (Selected)

Anesthesia Research Logo

Prof. Dr. Marco Ranucci, IRCCS Policlinico San Donato, Italy
| Editorial | view inaugural issue

anaesthetic medications; blood and fluid management; pain management; critical care; critical illness | view journal scope | submit an article

Complications Logo

Dr. Giovanni E. Cacciamani, University of Southern California, USA
| Editorial | view inaugural issue

surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article

Laboratories Logo

Prof. Dr.  Gassan Hodaifa, Universidad Pablo de Olavide, Spain
| Editorial | view inaugural issue

laboratory management; laboratory safety; protective equipment; laboratory problems and challenges; laboratory Innovation | view journal scope | submit an article

Pets Logo

Prof. Dr. Jan S. Suchodolski, Texas A&M University, USA
| Editorial | view inaugural issue

companion animals health and disease; veterinary care and nutrition; genetics and genomics; behavior and welfare; human-animal relations | view journal scope | submit an article

Real Estate Logo

Prof. Dr. Pierfrancesco De Paola, University of Naples Federico II, Italy
| Editorial | view inaugural issue

real estate appraisal; economic and financial valuation of real estate projects; sustainable real estate; housing and urban economics | view journal scope | submit an article

We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.

1 July 2024
Meet Us at the 31st International Carbohydrate Symposium (ICS2024), 14–19 July 2024, Shanghai, China


MDPI will be attending the 31st International Carbohydrate Symposium (ICS2024), which will be held from 14 to 19 July 2024 in Shanghai, China.

ICS2024 will follow the convention of the previous ICS symposiums to provide a global forum for researchers engaging in all aspects of carbohydrates. Besides classical topics on carbohydrate chemistry, chemical glycobiology, and glycobiology, the current developments of carbohydrates and glycotechnologies in the fields of the diagnosis and therapy of diseases, nutrients and cosmetics, agriculture and biofuels, and materials will be highlighted. ICS2024 will reflect the state-of-art as well as future trends of the glycosciences and forge communication and corporations between glycoscientists from various areas and disciplines.

The following topics will be covered:

  • Glycochemistry;
  • Glycobiology;
  • Carbohydrate drugs;
  • Sugar vaccines;
  • Carbohydrate materials.

The following MDPI journals will be represented at the symposium:

If you are planning to attend the above conference, we encourage you to visit our booth and speak to our representatives. We are eager to meet you in person and assist you with any queries that you may have.

For more information about the conference, please visit the official website at https://ics2024.casconf.cn/.

27 June 2024
Antibodies | Highly Viewed Papers in 2022–2023 in the Section “Humoral Immunity”


As all of the articles published in Antibodies (ISSN: 2073-4468) are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.

1. “A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)”
by Kristin Widyasari and Jinnam Kim
Antibodies 2023, 12(1), 5; https://doi.org/10.3390/antib12010005
Available online: https://www.mdpi.com/2073-4468/12/1/5

2. “Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance”
by Priscilla Gomes da Silva, José Augusto Seixas dos Reis, Marcio Nogueira Rodrigues, Quézia da Silva Ardaya and João Rodrigo Mesquita
Antibodies 2023, 12(1), 18; https://doi.org/10.3390/antib12010018
Available online: https://www.mdpi.com/2073-4468/12/1/18

3. “Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster”
by Chin Shern Lau, John Thundyil, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu et al.
Antibodies 2022, 11(4), 70; https://doi.org/10.3390/antib11040070
Available online: https://www.mdpi.com/2073-4468/11/4/70

4. “Detection of SARS-CoV-2 Antibodies: Comparison of Enzyme Immunoassay, Surrogate Neutralization and Virus Neutralization Test”
by Tatjana Vilibic-Cavlek, Maja Bogdanic, Ema Borko, Zeljka Hruskar, Denis Zilic, Thomas Ferenc, Irena Tabain, Ljubo Barbic, Mateja Vujica Ferenc, Ivana Ferencak et al.
Antibodies 2023, 12(2), 35; https://doi.org/10.3390/antib12020035
Available online: https://www.mdpi.com/2073-4468/12/2/35

5. “Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis”
by Mepur H. Ravindranath, Fatiha El Hilali, Carly J. Amato-Menker, Hajar El Hilali, Senthamil R. Selvan and Edward J. Filippone
Antibodies 2022, 11(3), 58; https://doi.org/10.3390/antib11030058
Available online: https://www.mdpi.com/2073-4468/11/3/58

6. “Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis”
by Mepur H. Ravindranath, Fatiha El Hilali, Carly J. Amato-Menker, Hajar El Hilali, Senthamil R. Selvan and Edward J. Filippone
Antibodies 2022, 11(3), 58; https://doi.org/10.3390/antib11030058
Available online: https://www.mdpi.com/2073-4468/11/3/58

7. “TLR7 and IgM: Dangerous Partners in Autoimmunity”
by Timm Amendt and Philipp Yu
Antibodies 2023, 12(1), 4; https://doi.org/10.3390/antib12010004
Available online: https://www.mdpi.com/2073-4468/12/1/4

8. “SARS-CoV-2 Virus-like Particles (VLPs) Specifically Detect Humoral Immune Reactions in an ELISA-Based Platform”
by Stefan Hirschberg, Hannes Bauer, Julian Kamhieh-Milz, Frauke Ringel, Christoph Harms, Omar Kamal Eddin, Axel Pruß, Katja Hanack and Kai Schulze-Forster
Antibodies 2022, 11(4), 76; https://doi.org/10.3390/antib11040076
Available online: https://www.mdpi.com/2073-4468/11/4/76

9. “Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study”
by Shinya Murata, Nobuyuki Oshima, Takashi Iwasa, Yukako Fukao and Miyuki Sawata
Antibodies 2023, 12(1), 22; https://doi.org/10.3390/antib12010022
Available online: https://www.mdpi.com/2073-4468/12/1/22

10. “Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals”
by Tatjana Vilibic-Cavlek, Vladimir Stevanovic, Snjezana Kovac, Ema Borko, Maja Bogdanic, Gorana Miletic, Zeljka Hruskar, Thomas Ferenc, Ivona Coric, Mateja Vujica Ferenc and et al.
Antibodies 2023, 12(4), 61; https://doi.org/10.3390/antib12040061
Available online: https://www.mdpi.com/2073-4468/12/4/61

27 June 2024
Antibodies | Highly Viewed Papers in 2022–2023 in Section the “Antibody-Based Diagnostics”


As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.

1. “IgG Avidity Test as a Tool for Discrimination between Recent and Distant Toxoplasma gondii Infection—Current Status of Studies”
by Lucyna Holec-Gąsior and Karolina Sołowińska
Antibodies 2022, 11(3), 52; https://doi.org/10.3390/antib11030052
Available online: https://www.mdpi.com/2073-4468/11/3/52

2. “New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond”
by Marino Paroli, Chiara Gioia and Daniele Accapezzato
Antibodies 2023, 12(1), 25; https://doi.org/10.3390/antib12010025
Available online: https://www.mdpi.com/2073-4468/12/1/25

3. “IgA Nephropathy: Current Treatment and New Insights”
by Dimitra Petrou, Petros Kalogeropoulos, George Liapis and Sophia Lionaki
Antibodies 2023, 12(2), 40; https://doi.org/10.3390/antib12020040
Available online: https://www.mdpi.com/2073-4468/12/2/40

4. “When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis”
by Marino Paroli and Maria Isabella Sirinian
Antibodies 2023, 12(4), 69; https://doi.org/10.3390/antib12040069
Available online: https://www.mdpi.com/2073-4468/12/4/69

5. “From Cereal Grains to Immunochemistry—What Role Have Antibodies Played in the History of the Home Pregnancy Test”
by Kinga Lis
Antibodies 2023, 12(3), 56; https://doi.org/10.3390/antib12030056
Available online: https://www.mdpi.com/2073-4468/12/3/56

6. “Antibodies for β2-Microglobulin and the Heavy Chains of HLA-E, HLA-F, and HLA-G Reflect the HLA-Variants on Activated Immune Cells and Phases of Disease Progression in Rheumatoid Arthritis Patients under Treatment”
by Mepur H. Ravindranath, Narendranath M. Ravindranath, Carly J. Amato-Menker, Fatiha El Hilali, Senthamil R. Selvan, Edward J. Filippone and Luis Eduardo Morales-Buenrostro
Antibodies 2023, 12(2), 26; https://doi.org/10.3390/antib12020026
Available online: https://www.mdpi.com/2073-4468/12/2/26

27 June 2024
Antibodies | Highly Viewed Papers from 2022–2023 in the Section “Antibody Discovery and Engineering”


As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.

1. “Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries”
by Huang Aric, Wei Jin, Ahmed S. Fahad, Brooklyn K. Mussman, Grazia Paola Nicchia, Bharat Madan, Matheus Oliveira de Souza, J. Daniel Griffin, Jeffrey L. Bennett, Antonio Frigeri et al.  
Antibodies 2022, 11(2), 39; https://doi.org/10.3390/antib11020039 
Available online: https://www.mdpi.com/2073-4468/11/2/39

2. “Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics”
by F. Donelson Smith, Robert H. Pierce, Thomas Thisted and Edward H. van der Horst
Antibodies 2023, 12(3), 55; https://doi.org/10.3390/antib12030055
Available online: https://www.mdpi.com/2073-4468/12/3/55

3. “Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants”
by Robert Pejchal, Anthony B. Cooper, Michael E. Brown, Maximiliano Vásquez and Eric M. Krauland
Antibodies 2023, 12(3), 54; https://doi.org/10.3390/antib12030054
Available online: https://www.mdpi.com/2073-4468/12/3/54

4. “Exploring Parametric and Mechanistic Differences between Expi293FTM and ExpiCHO-STM Cells for Transient Antibody Production Optimization”
by Jing Zhou, Guoying Grace Yan, David Cluckey, Caryl Meade, Margaret Ruth, Rhady Sorm, Amy S. Tam, Sean Lim, Constantine Petridis, Laura Lin et al.
Antibodies 2023, 12(3), 53; https://doi.org/10.3390/antib12030053
Available online: https://www.mdpi.com/2073-4468/12/3/53

5. “Cost-Effective Protein Production in CHO Cells Following Polyethylenimine-Mediated Gene Delivery Showcased by the Production and Crystallization of Antibody Fabs”
by Klaudia Meskova, Katarina Martonova, Patricia Hrasnova, Kristina Sinska, Michaela Skrabanova, Lubica Fialova, Stefana Njemoga, Ondrej Cehlar, Olga Parmar, Petr Kolenko et al.
Antibodies 2023, 12(3), 51; https://doi.org/10.3390/antib12030051
Available online: https://www.mdpi.com/2073-4468/12/3/51

6. “Quantitation and Identification of Therapeutic Anti-CD22 Monoclonal Antibodies in a Cell-Based ELISA Method”
by Shengyu Fu and Qi Zhao
Antibodies 2022, 11(3), 53; https://doi.org/10.3390/antib11030053
Available online: https://www.mdpi.com/2073-4468/11/3/53

7. “Cutaneous Lymphoma and Antibody-Directed Therapies”
by Alvise Sernicola, Christian Ciolfi, Paola Miceli and Mauro Alaibac
Antibodies 2023, 12(1), 21; https://doi.org/10.3390/antib12010021
Available online: https://www.mdpi.com/2073-4468/12/1/21

8. “Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement”
by Zenjiro Sampei, Christine Xing’er Koo, Frannie Jiuyi Teo, Ying Xiu Toh, Taku Fukuzawa, Siok Wan Gan, Takeru Nambu, Adrian Ho, Kiyofumi Honda, Tomoyuki Igawa et al.
Antibodies 2023, 12(2), 36; https://doi.org/10.3390/antib12020036
Available online: https://www.mdpi.com/2073-4468/12/2/36

9. “Generation of Antibodies Selectively Recognizing Epitopes in a Formaldehyde-Fixed Cell-Surface Antigen Using Virus-like Particle Display and Hybridoma Technology”
by Stefanie Schatz, Lena Willnow, Monika Winkels, Jamila Franca Rosengarten, Benjamin Theek, Ian C. D. Johnston and Jörn Stitz
Antibodies 2023, 12(3), 57; https://doi.org/10.3390/antib12030057
Available online: https://www.mdpi.com/2073-4468/12/3/57

10. “Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies”
by Lotte Jacobs, Kim Stobbelaar, Annick Heykers, Paul Cos and Peter Delputte
Antibodies 2023, 12(4), 62; https://doi.org/10.3390/antib12040062
Available online: https://www.mdpi.com/2073-4468/12/4/62

27 June 2024
Antibodies | Highly Viewed Papers in 2022–2023 in the Section “Antibody-Based Therapeutics”


As all of the articles published in our journal are in an open access format, you have free and unlimited access to the full texts. We welcome you to read our most highly viewed papers published in 2022 and 2023 listed below.

1. “IgY Antibodies as Biotherapeutics in Biomedicine”
by Diana León-Núñez, María Fernanda Vizcaíno-López, Magdalena Escorcia, Dolores Correa, Elizabeth Pérez-Hernández and Fernando Gómez-Chávez
Antibodies 2022, 11(4), 62; https://doi.org/10.3390/antib11040062
Available online: https://www.mdpi.com/2073-4468/11/4/62

2. “Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect”
by Toshihiko Tashima
Antibodies 2022, 11(4), 78; https://doi.org/10.3390/antib11040078
Available online: https://www.mdpi.com/2073-4468/11/4/78

3. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46

4. “Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1”
by Elisabeth Narayanan, Samantha Falcone, Sayda M. Elbashir, Husain Attarwala, Kimberly Hassett, Michael S. Seaman, Andrea Carfi and Sunny Himansu
Antibodies 2022, 11(4), 67; https://doi.org/10.3390/antib11040067
Available online: https://www.mdpi.com/2073-4468/11/4/67

5. “Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy”
by Chi Hun Song, Minchan Jeong, Hyukmin In, Ji Hoe Kim, Chih-Wei Lin and Kyung Ho Han
Antibodies 2023, 12(4), 72; https://doi.org/10.3390/antib12040072
Available online: https://www.mdpi.com/2073-4468/12/4/72

6. “Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses”
by Mireia Pelegrin, Soledad Marsile-Medun, Daouda Abba-Moussa, Manon Souchard and Mar Naranjo-Gomez
Antibodies 2022, 11(3), 50; https://doi.org/10.3390/antib11030050
Available online: https://www.mdpi.com/2073-4468/11/3/50

7. “The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors”
by Paolo Alimonti and L. Nicolas Gonzalez Castro
Antibodies 2023, 12(2), 27; https://doi.org/10.3390/antib12020027
Available online: https://www.mdpi.com/2073-4468/12/2/27

8. “An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions”
by Eleonora Prodi, Claudia Comacchio, Ettore Gilardoni, Cesare Di Nitto, Emanuele Puca, Dario Neri and Roberto De Luca
Antibodies 2023, 12(2), 29; https://doi.org/10.3390/antib12020029
Available online: https://www.mdpi.com/2073-4468/12/2/29

9. “Characterization of N-Terminal Asparagine Deamidation and Clipping of a Monoclonal Antibody”
by Jing Zhen, Jennifer Lee, Yueyang Wang, Lena McLaughlin, Fei Yang, Zhengjian Li and Jihong Wang
Antibodies 2023, 12(3), 59; https://doi.org/10.3390/antib12030059
Available online: https://www.mdpi.com/2073-4468/12/3/59

10. “Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity”
by Emenike Kenechi Onyido, David James, Jezabel Garcia-Parra, John Sinfield, Anna Moberg, Zoe Coombes, Jenny Worthington, Nicole Williams, Lewis Webb Francis, Robert Steven Conlan et al.
Antibodies 2023, 12(4), 65; https://doi.org/10.3390/antib12040065
Available online: https://www.mdpi.com/2073-4468/12/4/65

Back to TopTop